ALEMBIC PHARMACEUTICALS LIMITED
Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company provides products in various therapeutic areas, such as cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough, and animal health; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Maintains healthy dividend payout of 32.0%
Concerns1
- Negative free cash flow (βΉ6 Cr)
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ6.03 K Cr | β | βΉ503.00 Cr | β | β | 9.7% | 2.7% | -24.5% |
| Mar 2024 | βΉ5.87 K Cr | β | βΉ666.00 Cr | β | β | 13.6% | 14.1% | 91.9% |
| Mar 2023 | βΉ5.15 K Cr | β | βΉ347.00 Cr | β | β | 7.9% | 2.3% | -36.2% |
| Mar 2022 | βΉ5.04 K Cr | β | βΉ544.00 Cr | β | β | 10.3% | -0.6% | -50.4% |
| Mar 2021 | βΉ5.07 K Cr | β | βΉ1.10 K Cr | β | β | 21.5% | 22.6% | 13.2% |
| Mar 2020 | βΉ4.13 K Cr | β | βΉ969.00 Cr | β | β | 29.0% | 12.9% | 58.6% |
| Mar 2019 | βΉ3.66 K Cr | β | βΉ611.00 Cr | β | β | 22.5% | 24.3% | 44.8% |
| Mar 2018 | βΉ2.94 K Cr | β | βΉ422.00 Cr | β | β | 19.2% | -1.4% | -2.1% |
| Mar 2017 | βΉ2.99 K Cr | β | βΉ431.00 Cr | β | β | 23.1% | -0.8% | -38.3% |
| Mar 2016 | βΉ3.01 K Cr | β | βΉ699.00 Cr | β | β | 45.7% | 49.0% | 143.6% |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 6,267 |
| Total Expenses | 5,400 |
| EBIT / Operating Profit | 868 |
| OPM % | 14% |
| Other Income | 48 |
| Finance Costs | 91 |
| Depreciation & Amortisation | 287 |
| Profit Before Tax | 537 |
| Tax % | - |
| Net Profit / PAT | 444 |
| EPS (βΉ) | 22.59 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| ALEMBIC PHARMACEUTICALS LIMITEDthis co. | βΉ15.77 K Cr | βΉ6.03 K Cr | 35.50 | 3.00 | 15.18 | 2.7% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |